ABSTRACT
Background Limited guidance exists for the post-discharge care of ulcerative colitis (UC) patients hospitalized for moderate-severe flares.
Methods RAND methodology was used to establish appropriateness of inpatient and post-discharge steroid dosing, discharge criteria, follow-up, and post-discharge biologic or small molecule initiation. A literature review informed the panels voting, which occurred anonymously during two rounds before and after a moderated virtual session.
Results Methylprednisolone 40-60mg IV every 24 hours or hydrocortisone 300mg IV three times daily are appropriate for inpatient management, with methylprednisolone 40mg being appropriate if intolerant of higher doses. It is appropriate to discharge patients once rectal bleeding has resolved (Mayo sub score 0-1) and/or stool frequency has returned to baseline frequency and form (Mayo sub score 0-1). It is appropriate to discharge patients on 40mg of prednisone after observing patients for 24 hours in-hospital to ensure stability prior to discharge. For patients being discharged on steroids without in-hospital biologic or small molecule therapy initiation, it is appropriate to start anti-TNF therapy after discharge for anti-TNF naïve patients. For anti-TNF exposed patients it is appropriate to start vedolizumab or ustekinumab for all patients, and tofacitinib for those with a low risk of adverse events. It is appropriate to follow up patients clinically within 2 weeks, and with lower endoscopy within 4-6 months after discharge.
Conclusion We provide guidance on the inpatient and post-discharge management of UC patients hospitalized for moderate-severe flares.
WHAT IS KNOWN
Ulcerative colitis patients hospitalized for disease flares are a high-risk population
Guidance on evaluation and initial management during flares is provided, however, limited guidance exists on standardization of steroid management and post-discharge care
WHAT IS NEW HERE
Through a RAND Appropriateness Panel we provide guidance on the inpatient and post-discharge management of steroids, discharge criteria, post-discharge monitoring and management of biologics or small molecule therapies
These recommendations will help to bring uniformity to care for this high-risk population, and optimize outcomes in clinical practice
Competing Interest Statement
Parambir S. Dulai: Research support and/or consulting from Takeda, Janssen, Pfizer, Abbvie, Gilead, Lily, BMS, Novartis; stock options and board member for DigbiHealth; Licensing royalties from Precidiag. Victoria Rai: None Laura E. Raffals: Consulting from Janssen. Dana Lukin: Research support and/or consulting from Abbvie, Boehringer Ingelheim, BMS, Janssen, Palatin Technologies, Pfizer, Takeda; DSMB for WuXi Apptec; Scientific Advisory Board for PSI. David Hudesman: Research support from Jannsen and Pfizer; Consulting for Abbvie, BMS, Jannsen, Pfizer, Takeda. Gursimran S. Kochhar: Consulting for Lily. Oriana M. Damas: Research support and/or consulting from Pfizer. Jenny S. Sauk: Consulting or Speakers Bureau from Abbvie, CorEvitas, Pfizer, Prometheus. Alexander N. Levy: None Anthony Sofia: Consulting from Prometheus Biosciences. Anne Tuskey: Research support from AbbVie, Bristol Meyers Squibb, Eli Lily, Gilead Sciences, Parexal International/Takeda. Parakkal Deepak: Research support and/or consulting from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Pfizer, Prometheus Biosciences, Takeda Pharmaceuticals, Scipher Medicine and CorEvitas, LLC Andres Yarur: Consultant Takeda, Bristol Myers Squibb, Prometheus Labs and Arena pharmaceuticals. Speaker bureau, Bristol Myers Squibb. Anita Afzali: Consulting and/or speaking for Abbvie, Janssen, Bristol Myers Squibb, Pfizer, Takeda, Eli Lilly, Gilead, Arena Pharmaceuticals, TLL Pharmaceuticals, DiaSorin. Ashwin Ananthakrishnan: Served on the scientific advisory boards for Abbvie, Ikena Oncology. Research funding from the Chleck Family Foundation, Crohns and Colitis Foundation, and National Institutes of Health. Raymond K. Cross: Research support and/or consulting from Abbvie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, Prometheus, Samsung Bioepis, and Takeda Stephen B. Hanauer: Abbvie Consultant, Clinical Research (Institution), Speaker ; Allergan Consultant, Clinical Research (Institution) ;Amgen Consultant, Clinical Research (Institution); Arena Consultant, DSMB; Boehringer-Ingelheim Consultant, DSMB; BMS Consultant, DSMB; Celgene Consultant, Clinical Research (Institution); Celttrion Consultant; Genentech Consultant, Clinical Research, (Institution); Gilead Consultant, Clinical Research (Institution); GSK Consultant, Clinical Research (Institution); Janssen Consultant, Clinical Research (Institution), Speaker; Lilly Consultant, Clinical Research (Institution); Merck Consultant; Novartis Consultant, Clinical Research (Institution); Pfizer Consultant, Clinical Research (Institution), Speaker; Progenity Consultant; Prometheus Consultant, Clinical Research (Institution); Protagonist Consultant, DSMB; Receptos Consultant, Clinical Research (Institution), Salix (Consultant); Samsung Bioepis Consultant; Seres Therapeutics Consultant, Clinical Research (Institution); Takeda Consultant, Clinical Research (Institution), Speaker; UCB Consultant, Clinical Research (Institution), VHsquared Consultant. Corey A. Siegel: Consultant for Abbvie, BMS, Lilly, Janssen, Napo Pharmaceuticals, Pfizer, Prometheus, Takeda, Tellus Health. Speaker for CME activities for Abbvie, Janssen, Pfizer, Takeda. Grant support from Abbvie, Janssen, Pfizer and Takeda. Dr. Corey Siegel and Dr. Lori Siegel are co-founders of MiTest Health, LLC (software company). Technology developed by MiTest Health, LLC has been licensed to Takeda.
Funding Statement
This study was funded by an NIDDK U34 planning grant (Dulai P; DK126626-01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Guarantors of Article: Parambir S. Dulai, Victoria Rai, and Corey A. Siegel
Funding: This study was funded by an NIDDK U34 planning grant (Dulai P; DK126626-01). Dr. Dulai is supported by an American Gastroenterology Association Research Scholar Award. Dr. Deepak is supported by a Junior Faculty Development Award from the American College of Gastroenterology and IBD Plexus of the Crohn’s & Colitis Foundation.
Disclosures Parambir S. Dulai: Research support and/or consulting from Takeda, Janssen, Pfizer, Abbvie, Gilead, Lily, BMS, Novartis; stock options and board member for DigbiHealth; Licensing royalties from Precidiag.
Victoria Rai: None
Laura E. Raffals: Consulting from Janssen.
Dana Lukin: Research support and/or consulting from Abbvie, Boehringer Ingelheim, BMS, Janssen, Palatin Technologies, Pfizer, Takeda; DSMB for WuXi Apptec; Scientific Advisory Board for PSI.
David Hudesman: Research support from Jannsen and Pfizer; Consulting for Abbvie, BMS, Jannsen, Pfizer, Takeda.
Gursimran S. Kochhar: Consulting for Lily.
Oriana M. Damas: Research support and/or consulting from Pfizer.
Jenny S. Sauk: Consulting/ Speaker’s Bureau from Abbvie, CorEvitas, Pfizer, Prometheus. Alexander N. Levy: None
Anthony Sofia: Consulting from Prometheus Biosciences.
Anne Tuskey: Research support from AbbVie, Bristol Meyers Squibb, Eli Lily, Gilead Sciences, Parexal International/Takeda.
Parakkal Deepak: Research support and/or consulting from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Pfizer, Prometheus Biosciences, Takeda Pharmaceuticals, Scipher Medicine and CorEvitas, LLC
Andres Yarur: Consultant Takeda, Bristol Myers Squibb, Prometheus Labs and Arena pharmaceuticals. Speaker bureau, Bristol Myers Squibb.
Anita Afzali: Consulting and/or speaking for Abbvie, Janssen, Bristol Myers Squibb, Pfizer, Takeda, Eli Lilly, Gilead, Arena Pharmaceuticals, TLL Pharmaceuticals, DiaSorin.
Ashwin Ananthakrishnan: Served on the scientific advisory boards for Abbvie, Ikena Oncology. Research funding from the Chleck Family Foundation, Crohn’s and Colitis Foundation, and National Institutes of Health. Raymond K. Cross: Research support and/or consulting from Abbvie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, Prometheus, Samsung Bioepis, and Takeda
Stephen B. Hanauer: Abbvie Consultant, Clinical Research (Institution), Speaker ; Allergan Consultant, Clinical Research (Institution) ;Amgen Consultant, Clinical Research (Institution); Arena Consultant, DSMB; Boehringer-Ingelheim Consultant, DSMB; BMS Consultant, DSMB; Celgene Consultant, Clinical Research (Institution); Celttrion Consultant; Genentech Consultant, Clinical Research, (Institution); Gilead Consultant, Clinical Research (Institution); GSK Consultant, Clinical Research (Institution); Janssen Consultant, Clinical Research (Institution), Speaker; Lilly Consultant, Clinical Research (Institution); Merck Consultant; Novartis Consultant, Clinical Research (Institution); Pfizer Consultant, Clinical Research (Institution), Speaker; Progenity Consultant; Prometheus Consultant, Clinical Research (Institution); Protagonist Consultant, DSMB; Receptos Consultant, Clinical Research (Institution), Salix (Consultant); Samsung Bioepis Consultant; Seres Therapeutics Consultant, Clinical Research (Institution); Takeda Consultant, Clinical Research (Institution), Speaker; UCB Consultant, Clinical Research (Institution), VHsquared Consultant.
Corey A. Siegel: Consultant for Abbvie, BMS, Lilly, Janssen, Napo Pharmaceuticals, Pfizer, Prometheus, Takeda, Tellus Health. Speaker for CME activities for Abbvie, Janssen, Pfizer, Takeda. Grant support from Abbvie, Janssen, Pfizer and Takeda. Dr. Corey Siegel and Dr. Lori Siegel are co-founders of MiTest Health, LLC (software company). Technology developed by MiTest Health, LLC has been licensed to Takeda.
Data Availability
All data produced in the present work are contained in the manuscript